The double-helix derailed: The story of the BRCA patent

The Lancet

Volumn 376, Issue 9738, 2010, Pages 314-315

  Matloff, Ellen T ^a   Brierley, Karina L ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER PREVENTION; CLINICAL LABORATORY; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE MUTATION; HEALTH CARE COST; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; MEDICAL TECHNOLOGY; NOTE; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RISK REDUCTION;

EID: 77955697942     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61150-6     Document Type: Note

References (21)

1. Association for Molecular Pathology et al against United States Patent and Trademark Office http://www.aclu.org/files/assets/2010-3-29-AMPvUSPTO- Opinion.pdf March 29, 2010 (accessed July 14, 2010).
2. AS Kesselheim, MM Mello Gene patenting - is the pendulum swinging back? N Engl J Med 362 2010 1855 1858
3. SP Westphal Your money or your life New Sci 175 2002 29 35
4. A Lecrubier Patents and public health EMBO Rep 3 2002 1120 1122
5. TB Kepler, C Crossman, R Cook-Deegan Metastasizing patent claims on BRCA1 Genomics 95 2010 312 314
6. D Ford, DF Easton, DT Bishop, SA Narod, DE Goldgar the Breast Cancer Linkage Consortium Risks of cancer in BRCA1-mutation carriers Lancet 343 1994 692 695
7. M King, J Marks, JB Mandell Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643 646
8. S Koritz Carlson curve http://www.progressdaily.com/2009/09/09/carlson- curve Sept 9, 2009 (accessed April 9, 2010).
9. B Williams-Jones "Be ready against cancer, now": direct-to-consumer advertising for genetic testing New Genet Soc 25 2006 89 107
10. SE Gollust, SC Hull, BS Wilfond Limitations of direct-to-consumer advertising for clinical genetic testing JAMA 288 2002 1762 1767
11. ER Gold, J Carbone Myriad Genetics: In the eye of the policy storm Genet Med 12 2010 S39 S70
12. American Civil Liberties Union BRCA - supplemental declaration of Ellen Matloff http://www.aclu.org/free-speech-womens-rights/brca-supplemental- declaration-ellen-matloff Jan 20, 2010 (accessed July 14, 2010).
13. Myriad Genetic Account Executive Dallas East, TX http://www.maxhire.net/ cp/?E95F65361F43515B7E541321 (accessed July 14, 2010).
14. T Doksum, BA Bernhardt, NA Holtzman Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? Genet Med 5 2003 99 105
15. K Greendale, RE Pyeritz Empowering primary care health professionals in medical genetics: How soon? How fast? How far? Am J Med Genet 106 2001 223 232
16. L Wideroff, ST Vadaparampil, MH Greene, S Taplin, L Olson, AN Freedman Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians J Med Genet 42 2005 749 755
17. Brierley KL, Campfield D, Ducaine W, et al. Errors in delivery of cancer genetics services: implications for practice. Connecticut Med (in press).
18. Anon Q&A: more patients experience inadequate genetic testing, advocacy official says. Pharmacogenomics Reporter http://www.genomeweb.com/ dxpgx/more-patients-experience-inadequate-genetic-testing-advocacy-official- says Jan 7, 2009 (accessed Oct 28, 2009).
19. T Ray Myriad defends policy of urging docs to genetically counsel BRACAnalysis customers. Pharmacogenomics Reporter http://www.genomeweb.com/ dxpgx/myriad-defends-policy-urging-docs-genetically-counsel-bracanalysis- customers Feb 10, 2010 (accessed July 14, 2010).
20. Myriad Genetic Laboratories, Inc Myriad Genetics Annual Report 2009 http://files.shareholder.com/downloads/MYGN/962867881x0x321196/ 42ECFDDF-2D7D-48DC-AAFE-3471F4CF6B91/Annual-Report-2009.pdf (accessed April 9, 2010).
21. Myriad Genetic Laboratories, Inc. Myriad financial assistance program financial criteria http://www.myriad.com/lib/mfap/MFAP-Financial-Criteria.pdf Feb 3, 2010 (accessed April 9, 2010).